Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China

Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China

BackgroundsRobust evidence have demonstrated the beneficial effect of Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in T2D patients with cardiovascular diseases and chronic kidney disease. Multiple studies analyzed patterns and predictors...

Full description

Bibliographic Details
Main Authors:	Cao Li, Shanshan Guo, Jiping Huo, Yiming Gao, Yilong Yan, Zhigang Zhao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-10-01
Series:	Frontiers in Endocrinology
Subjects:	SGLT2i GLP-1RA type 2 diabetics cardiovascular diseases chronic kidney disease
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2022.987081/full

Similar Items

Utilization of glucagon-like peptide-1 receptor agonists in children and adolescents in China: a real-world study
by: Yilong Yan, et al.
Published: (2023-06-01)

Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study
by: Phyo T. Htoo, et al.
Published: (2024-02-01)

The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus
by: Teodor Salmen, et al.
Published: (2023-03-01)

Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium–Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure
by: Giovanna Gallo, et al.
Published: (2024-02-01)

National Trends in Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Glucagon‐like Peptide‐1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020
by: Rishav Adhikari, et al.
Published: (2022-05-01)

Patient preferences for glucagon-like peptide-1 receptor–agonist treatment attributes
by: Thieu VT, et al.
Published: (2019-04-01)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
by: Apurva Khedagi, et al.
Published: (2023-03-01)

Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials
by: Yunpeng Gu, et al.
Published: (2023-03-01)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
by: Panagiotis I. Georgianos, et al.
Published: (2022-02-01)

Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection
by: Erin D. Michos, et al.
Published: (2023-06-01)

Drug Therapies for Diabetes
by: Roni Weinberg Sibony, et al.
Published: (2023-12-01)

Role of metformin, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) receptor agonists, and orlistat based multidrug therapy in glycemic control, weight loss, and euglycemia in diabesity: A real-world experience
by: Deep Dutta, et al.
Published: (2019-01-01)

Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes
by: Věra Čertíková Chábová, et al.
Published: (2022-03-01)

Glucagon-Like Peptide-2 and the Enteric Nervous System Are Components of Cell-Cell Communication Pathway Regulating Intestinal Na+/Glucose Co-transport
by: Andrew W. Moran, et al.
Published: (2018-10-01)

Glucagon‐like peptide agonists: A prospective review
by: Zamara Mariam, et al.
Published: (2024-01-01)

Risk of Fracture With Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis Combining 177 Randomized Controlled Trials With a Median Follow-Up of 26 weeks
by: Sanbao Chai, et al.
Published: (2022-07-01)

The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease
by: Yuan Lin, et al.
Published: (2023-03-01)

Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment
by: Stefano Ciardullo, et al.
Published: (2023-08-01)

Weight changes following antidiabetic mediation use: Real‐world evidence from health system data
by: Beini Lyu, et al.
Published: (2022-10-01)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
by: A. Delgado, et al.
Published: (2021-04-01)

Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysisResearch in context
by: Irene Caruso, et al.
Published: (2023-10-01)

Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
by: Sarah L. Armour, et al.
Published: (2022-02-01)

High glucose promotes the progression of colorectal cancer by activating the BMP4 signaling and inhibited by glucagon-like peptide-1 receptor agonist
by: Bingwei Ma, et al.
Published: (2023-06-01)

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
by: Teshome G, et al.
Published: (2020-09-01)

Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide
by: Maria Elena Lunati, et al.
Published: (2024-01-01)

Patterns of new glucagon‐like peptide‐1 receptor agonist use in patients with type 2 diabetes during 2014–2019 from a US database: prescriber and patient characteristics
by: Ildiko Lingvay, et al.
Published: (2023-02-01)

Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis
by: Yoon Ji Kim, et al.
Published: (2020-08-01)

Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
by: Angelica Cersosimo, et al.
Published: (2024-03-01)

The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients
by: Israel Mazin, et al.
Published: (2022-03-01)

Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model
by: Ana Claudia Cavalcante Nogueira, et al.
Published: (2023-10-01)

SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study
by: Zheer Kejlberg Al-Mashhadi, et al.
Published: (2022-08-01)

Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity
by: Erin D. Michos, et al.
Published: (2023-06-01)

The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States
by: Wayne Weng, et al.
Published: (2019-07-01)

Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study
by: Yan Jiang, et al.
Published: (2024-03-01)

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
by: Anoushka Krishnan, et al.
Published: (2023-04-01)

The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus—A Systematic Review
by: Ioana-Cristina Bica, et al.
Published: (2023-04-01)

Effectiveness and clinical benefits of new anti-diabetic drugs: A real life experience
by: Piazzolla Giuseppina, et al.
Published: (2022-07-01)

Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis
by: David Tak Wai Lui, et al.
Published: (2022-08-01)

Glycaemia and body weight are regulated by sodium-glucose cotransporter 1 (SGLT1) expression via O-GlcNAcylation in the intestine
by: Kimihiro Nishimura, et al.
Published: (2022-05-01)